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Introduction 47
Eltrombopag is a thrombopoietin receptor (also known as c-Mpl or MPL) 48 agonist that is used for the treatment of thrombocytopenia [1] [2] [3] . Its use has also been 49 suggested for the treatment of cytopenias after haematopoietic stem cell 50 transplantations and case reports support its safety and efficacy [4] [5] [6] [7] [8] [9] . 51
Human cytomegalovirus (HCMV) reactivation and HCMV-associated disease 52 are leading reasons for the failure of haematopoietic stem cell transplantations [10-53 12] . Anti-HCMV drugs including ganciclovir, cidofovir, and foscarnet are available, but 54 their use is associated with severe side effects [13] . In particular, the use of ganciclovir 55 (and its prodrug valganciclovir), the mainstay treatment for cytomegalovirus disease, 56 is associated with severe haematological side effects including thrombocytopenia [14-57 16] . 58 A case report described the use of eltrombopag in an immunocompetent patient 59 who suffered from human cytomegalovirus (HCMV)-associated thrombocytopenia 60 [17] . Immunosuppressive treatment for thrombocytopenia (prednisone, intravenous 61 immunoglobulin, dapsone) in combination with antiviral therapy (ganciclovir/ 62 valganciclovir, HCMV hyperimmune globulin) only resulted in a temporary platelet 63 response with subsequent relapse. A change to eltrombopag intended to increase 64 platelet counts without immunosuppressive therapy resulted in a durable increase in 65 platelet levels, no evidence of HCMV viraemia, and the resolution of symptoms [17] . 66
The observed effects were attributed to eltrombopag overcoming HCMV-induced 67 suppression of platelet production [17] . However, we hypothesised that direct antiviral 68 effects may also have contributed to the beneficial outcome in the case report of the 69 patient with HCMV-associated thrombocytopenia [17] . Indeed, we found that 70 eltrombopag exerts anti-HCMV effects via iron chelation. 71
Materials and Methods 72
Drugs 73 Eltrombopag (as its orally active ethanolamine salt eltrombopag olamine) was 74 purchased from Selleck Chemicals (via Absource Diagnostics GmbH, Munich 75 Germany), deferasirox and ganciclovir from MedChemExpress (via Hycultec, 76 Beutelsbach, Germany), and cidofovir from Cayman Chemical (via Biomol GmbH, 77
Hamburg, Germany). 78 79
Cells and viruses 80
Primary human foreskin fibroblasts (HFFs) and adipose-derived adult 81 mesenchymal stem cells (ASCs) were cultivated as previously described [18, 19] . 82
The wild type HCMV strain Hi91 was isolated from the urine of an AIDS patient 83 with HCMV retinitis as described previously [20] . HCMV strains Davis and Towne were 84 received from ATCC (Manassas, VA, USA). Virus stocks were prepared in HFFs 85 maintained in minimal essential medium (MEM) supplemented with 4% FCS. U1, U59, 86 and U75 are patient isolates, which were isolated as previously described [20, 21] . 87
Virus stocks were prepared in HFFs maintained in minimal essential medium ( 
Viability assay 122
Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-123 diphenyltetrazolium bromide (MTT) dye reduction assay as described previously [23] . 124
Confluent cell cultures in 96-well microtiter plates were incubated with culture medium 125 containing serial dilutions of the indicated substances. After five days of incubation 126 MTT (1 mg/ml) was added and after an additional four hours, cells were lysed in a 127 buffer containing 20% (w/v) SDS and 50% N,N-dimethylformamide adjusted to pH 4.5. 128
Absorbance was determined at 570 nm for each well using a 96-well multiscanner. Table 1) . 180
Pre-incubation and drug addition during the one-hour virus adsorption period did not 181 or only modestly affect virus replication. This shows that eltrombopag does not 182 primarily interfere with virus binding to host cells and virus internalisation but needs to 183 be present during virus replication to exert its anti-HCMV effects. Drug addition one 184 hour or 24h post infection was sufficient to achieve maximum inhibition of HCMV LA 185 expression ( Figure 2B , Suppl. Table 1 ). This, together with the observed lack of 186 inhibition of HCMV IEA expression, indicates that eltrombopag inhibits the late stages Table 1) . 190 191
Eltrombopag inhibits HCMV expression via iron chelation 192
Eltrombopag was developed as thrombopoietin receptor agonist [1] [2] [3] . 193 However, it is unlikely that eltrombopag inhibits HCMV replication via thrombopietin 194 receptor activation, because fibroblasts do not express the thrombopoietin receptor 195
[28]. In agreement, eltrombopag also inhibited murine cytomegalovirus replication in 196 murine NIH/3T3 fibroblasts ( Figure 3A with equimolar Fe(III)Cl3 concentrations to investigate whether iron chelation is the 203 mechanism by which eltrombopag exerts its anti-HCMV effects ( Figure 3B ). Since 204 equimolar Fe(III)Cl3 concentrations prevented the anti-HCMV effects of eltrombopag 205 ( Figure 3B ), we concluded that iron chelation is the main mechanism of eltrombopag's 206 anti-HCMV activity. 207 208
Eltrombopag exerts synergistic effects with ganciclovir 209
Next, we tested eltrombopag in combination with ganciclovir, the mainstay of Hi91. The clinical isolates U1, U59, and U75 were isolated from the urine of patients 223 as previously described [20, 21] . U1 and U59 harbour a A987G mutation in the HCMV 224 DNA polymerase UL54 (Table 1) , which is known to confer combined ganciclovir and 225 cidofovir resistance [42, 43] . U1 also displays a C607Y mutation in the HCMV kinase 226 UL97 (Table 1) , which is associated with ganciclovir resistance [44, 45] . In agreement, 227 U1 and U59 were characterised by high ganciclovir and cidofovir IC50s ( The eltrombopag IC50s ranged from 99nM (U1 in HFFs) to 4331nM (Hi91 in 232 ASCs) ( Figure 5A , Suppl. Table 2 ). When compared across the two cell types, the 233 different HCMV strains and clinical isolates displayed similar eltrombopag sensitivity, 234 apart from U1, which appeared to be particularly sensitive to eltrombopag in HFFs and 235 ASCs ( Figure 5B ). The average HCMV sensitivity to eltrombopag was very similar in 236 both cell types ( Figure 5C ). 237
To confirm the relevance of iron chelation as mechanism of the anti-HCMV The anti-HCMV effects of eltrombopag are unlikely to be caused by action on 261 the thrombopoietin receptor, since eltrombopag was effective in cell types that do not 262 express the thrombopoietin receptor, which is expressed in haematopoietic cells 263 [28, 29] . In agreement, eltrombopag also exerted antiviral effects in mouse fibroblasts 264 infected with murine CMV, although the haematological effects of eltrombopag are 265 known to be species-specific and to not affect mice [28, 29] . 
